NCT06099886Not yet recruiting

Repurposing Lithium for Parkinson's Disease

Name: Clinical Trial NCT06099886
Creator: State University of New York at Buffalo
Keywords: Parkinson's Disease, Lithium aspartate, Phase 1, dietary supplement, clinical trial

Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: A Phase I Trial

State University of New York at BuffaloPhase 1ClinicalTrials.govdietary supplement

Verified

Study focus

Disease/Condition: Parkinson's Disease
Drug/Device/Intervention: Lithium aspartate
Study type: Interventional
Intervention type: dietary supplement

Sponsor & location

Primary sponsor: State University of New York at Buffalo

Timeline & enrollment

Phase: Phase 1
Start date: Oct 01, 2023
End date: May 01, 2025
Enrollment: 15 participants

Primary outcome

MRI-derived free water (FW) levels,Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression.

Summary

This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.

ICD-10 classifications

Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismPostencephalitic parkinsonism

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06099886
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06099886 through Pure Global AI's free database. This Phase 1 trial is sponsored by State University of New York at Buffalo and is currently Not yet recruiting. The study focuses on Parkinson's Disease. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.